BioXcel Therapeutics Inc
Research BioXcel Therapeutics Inc (BTAI) on Bullrun: market cap USD 43.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBTAI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 43.23M
- Financial periodFY2025
- RevenueUSD 642.00K
- Revenue growth-71.7%
- Net income-USD 69.90M
- Free cash flow-USD 57.62M
- Gross margin74.5%
Valuation Snapshot
latest market cap is USD 43.23M.
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Frequently asked questions
What is BioXcel Therapeutics Inc's market cap?
BioXcel Therapeutics Inc's market capitalization is USD 43.23M.
What does BioXcel Therapeutics Inc do?
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.